| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1014: Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | alectinib (Alecensa®) |
| Formulation | 150 mg hard capsules |
| Reference number | 4091 |
| Indication | Treatment of ALK-positive non-small cell lung cancer (NSCLC) - adjuvant therapy |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/10/2024 |
| NICE guidance | TA1014: Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer |